publication venue for
- A 10-year population-based prevalence study of the burden of generalized pustular psoriasis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics 2023
- A 10-year population-based prevalence study of the burden of palmoplantar pustulosis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics 2023
- A 3-year population-based incidence study of the burden of generalized pustular psoriasis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics 2023
- A 3-year population-based incidence study of the burden of palmoplantar pustolosis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics 2023
- Long-term efficacy and safety of guselkumab in psoriasis patients with and without psoriatic arthritis: A pooled analysis from VOYAGE 1 and VOYAGE 2 2019
- Secukinumab demonstrates significant improvement of disease activity and health-related quality of life in Canadian psoriasis patients in a real-world setting 2018
- Sociodemographic and baseline disease profile of patients with moderate to severe chronic plaque psoriasis treated with secukinumab vs. other treatments in Canadian routine clinical care: Results from the PURE registry 2018
- Early real-world effectiveness of secukinumab in the treatment of psoriasis in Canada: Retrospective analysis of patient support program data 2017
- Secukinumab provides greater 52-week sustained relief from dermatology-related quality of life impact on clothing choice and sexual function than ustekinumab 2017
- Secukinumab provides greater cumulative 52-week skin clearance and quality of life benefit in patients with moderate-to-severe plaque psoriasis than ustekinumab: An area under the curve analysis 2017
- Comparison of guselkumab with placebo and adalimumab on health-related quality of life in a phase 2b clinical trial X-PLORE 2016
- Major emotional and physical complications among survivors of Stevens Johnson syndrome and toxic epidermal necrolysis 2016
- Cutaneous disease is associated with higher early systemic lupus disease activity 2015
- Patient preferences and willingness to pay for enhancements to subcutaneous injection devices used to treat psoriasis 2014
- A systematic review of patient-reported outcome instruments of nonmelanoma skin cancer in the dermatologic population 2013
- A study of systemic scleroderma in the southern region of Brazil: Cutaneous manifestations and clinical and laboratory marker association 2009
- Combining biologics and cyclosporine for psoriasis treatment 2009
- Comparison of identical patch test allergens front different commercial sources in Brazil 2009
- Cost analysis of system therapy for psoriasis in Brazil 2009
- Efalizumab's effectiveness in treating plaque psoriasis affecting the hands/feet, scalp, and nails: Interim subanalysis of the Canadian RESTORE study data 2009
- Immune reconstitution inflammatory syndrome surrounding molluscum contagiosum 2009
- Physical and psychological assessment follow-up for moderate and severe psoriasis using acitretin 2009
- Prevalence of metabolic syndrome among patients with psoriasis at a dermatologic service in the south of Brazil 2009
- Two identical triplet sisters with different psoriasis presentation form and response to etanercept without genetic mutation at inflammatory cytokine gene promoters 2009
- A practical understanding of mean percent PASI reduction for biologics 2008
- Infliximab-induced pustular psoriasis 2008
- Palmoplantar keratoderma in a patient with a chromosome 12q deletion 2008
- Similar responses with adalimumab therapy in patients with moderate versus severe psoriasis: Subanalysis of multiple placebo-controlled trials 2008
- Erythema multiforme-like with topical diphenylcyclo-propenone 2006
- Objective evaluation of wrinkle improvement in a cosmetic treatment using digital photography 2006
- Approach to Mycosis Fungoides in children: Consensus-based recommendations.. 91:1078-1085. 2024
- Prevalence and risk factors of interstitial lung disease in dermatomyositis: A retrospective study.. 91:1219-1221. 2024
- Organic solvent exposure and systemic sclerosis: A retrospective cohort study based on the Canadian Scleroderma Research Group registry. 90:605-607. 2024
- 43266 A 10-year population-based prevalence study of the burden of generalized pustular psoriasis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics. 89:AB106-AB106. 2023
- 43322 A 10-year population-based prevalence study of the burden of palmoplantar pustulosis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics. 89:AB107-AB107. 2023
- 44100 A 3-year population-based incidence study of the burden of generalized pustular psoriasis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics. 89:AB107-AB107. 2023
- 44118 A 3-year population-based incidence study of the burden of palmoplantar pustolosis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics. 89:AB107-AB107. 2023
- Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: A multisite population-based cohort study. 89:243-253. 2023
- Management of adult generalized pustular psoriasis using biologics: A systematic review. 89:417-419. 2023
- Geographical distribution of systemic sclerosis in Canada: An ecologic study based on the Canadian Scleroderma Research Group. 87:1095-1097. 2022
- Reporting of primary outcome measures and sample size calculations in randomized controlled trials in dermatology journals. 87:912-914. 2022
- Management of pediatric generalized pustular psoriasis using biologics: An evidence-based review. 87:484-486. 2022
- 26423 Psychometric properties of patient-reported outcome measures for nail conditions: A systematic review. 85:AB18-AB18. 2021
- Trends in mortality and cause-specific mortality among patients with psoriasis and psoriatic arthritis in Ontario, Canada. 84:1302-1309. 2021
- Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors. 84:1169-1171. 2021
- Guselkumab dosing interval optimization in adult patients with psoriasis: A retrospective, multicenter case series. 83:1813-1814. 2020
- Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study. 81:1405-1409. 2019
- Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study. 78:741-748. 2018
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. 76:60-69.e9. 2017
- Treatment of toxic epidermal necrolysis in North America. 73:876-877.e2. 2015
- Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. 71:141-150. 2014
- Stem cell transplantation in advanced cutaneous T-cell lymphoma. 58:645-649. 2008
- Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. 57:1-27. 2007
- Prognostic factors for life expectancy in nonagenarians with nonmelanoma skin cancer: Implications for selecting surgical candidates. 47:419-422. 2002
- Measuring quality of life in people referred for specialist care of acne: Comparing generic and disease-specific measures. 43:229-233. 2000
- Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. 43:54-60. 2000
- Topical calcipotriol in childhood psoriasis. 36:203-208. 1997
- A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. 29:1008-1012. 1993
- Combined treatment with oral etretinate and electron beam therapy in patients with cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). 26:960-967. 1992
- Actinic prurigo: Clinical features and prognosis. 26:683-692. 1992
- Polymyositis: A manifestation of chronic graft-versus-host disease. 25:560-562. 1991
- Serum sickness—like illness and leukocytoclastic vasculitis after intravenous streptokinase. 24:652-653. 1991
- Langerhans cell histiocytosis in monozygotic twins. 24:32-37. 1991
- HLA typing in actinic prurigo. 22:1019-1023. 1990
- PRETIBIAL EPIDERMOLYSIS-BULLOSA - REPORT OF A CASE. 22:346-350. 1990
- Pretibial epidermolysis bullosa: Report of a case. 22:346-350. 1990
- Thyroid evaluation in alopecia areata in children. 19:1118-1118. 1988